The phosphorylation of the two-chain form of vitronectin by protein kinase A is heparin dependent  by Chain, Daniel et al.
Volume 269, number 1, 221-225 FEBS 08740 August 1990 
The phosphorylation of the two-chain form of vitronectin by protein 
kinase A is heparin dependent* 
Daniel Chain**, Beatriz Korc-Grodzicki, Tamar Kreizman and Shmuel Shaltiel 
Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, 76100, Israel 
Received 21 June 1990 
In circulating blood, vi&one&in occurs in two forms: a single-chain (75 kDa) and an endogenously clipped two-chain form (65 kDa and 10 kDa) 
held together by a disulfide bridge. The 75 kDa form was previously shown to be phosphorylated at Seti78 by protein kinase A, released by physio- 
logically stimulated platelets. By contrast, at pH 7.5 the two-chain form is not phosphorylated at all. Heparin or heparan sulfate are shown here 
to modulate the conformation of clipped vitronectin at physiological pH, exposing Se2’s and allowing its stoichiometric phosphorylation by the 
kinase. At this pH the two-chain form of vitronectin in plasma exhibits a higher affinity for heparin, and behaves as a flexible molecule, which 
can conformationally respond to heparin and heparan sulfate, effecters involved in vitronectin function. 
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1. INTRODUCTION [8,10]. It is currently assumed that there are ‘no major 
functional differences between these forms’ [4]. 
Vitronectin is a multifunctional adhesive protein 
which plays an important role in blood coagulation and 
in the immuno-complement system [l-5]. It has been 
cloned and sequenced [6,7]: At its N-terminus (posi- 
tions l-44) it has a sequence identical to somatomedin 
B, followed by an Arg-Gly-Asp epitope (positions 
45-47) involved in cell adhesion and spreading [l-3]. It 
also has a heparin-binding domain (positions 348-379) 
which seems to be involved in the inhibition of the 
heparin-catalyzed formation of the thrombin- 
antithrombin III complex and in other functions of 
vitronectin [4,5]. 
In circulating blood, vitronectin occurs in two 
molecular forms: a single-chain 75 kDa form (V& and 
a clipped form composed of two chains (65 kDa and 10 
kDa) which are held together by a disulfide bridge 
(VSS + 10) [2,8,9]. The endogenous proteinase responsi- 
ble for this cleavage has not been identified, but the 
cleavage was shown to occur at the Arg3”-Ala3*’ bond 
We have recently shown that V75 is specifically 
phosphorylated at Ser3’* by PKA and that this kinase 
is specifically released (together with its co-substrate, 
ATP) upon physiological stimulation of blood platelets 
[11,12]. By COntraSt to v75, V65 + 10 WaS not 
phosphorylated at all at physiological pH [ 12,131, in 
spite of the fact that Ser3’* and the complete recogni- 
tion sequence of protein kinase A (Arg-Arg-Pro-Ser- 
Arg) are still present in the 65 kDa chain of V65 + 10 [lo]. 
This paper shows that, at physiological pH, v65 + 10 oc- 
curs in two distinct conformations: one in which Ser3’* 
is inaccessible to phosphorylation by PICA, and another 
in which Ser3’* is exposed and accessible to 
stoichiometric phosphorylation by this kinase. Heparin 
and heparan-sulfate induce and stabilize the conforma- 
tion which exposes Ser3’* 
2. MATERIALS AND METHODS 
2.1. Materials 
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Abbreviations: GAG, glycosaminoglycan; Hepes, iV-2-hydroxyethyl 
piperazine-hr’-2-ethanesulfonic acid; Mes, 2-(N-morpholino)- 
ethanesulfonic acid; PKA, protein kinase A; R, reducing conditions; 
NR, non-reducing conditions; SDS-PAGE, polyacrylamide gel elec- 
trophoresis in the presence of sodium dodecylsulfate; V~S, the one 
chain form of vitronectin; V65 + 10, the two-chain form of vitronectin 
Freshly-frozen human plasma was obtained from the blood bank 
of the Tel Hashomer Medical Center, Ramat Gan, Israel. 2-(N- 
Morpholino) ethanesulfonic acid, (N-2_hydroxyethylpiperazine- 
N’-Zethane sulfonic acid), ATP, heparin, heparan sulfate, chon- 
droitin sulfate C, dextran sulfate, polyethylene glycol (Mr= 3350) 
phenyl-methyl sulfonyl fluoride, benzamidine hydrochloride, reduc- 
ed glutathione and affinity purified goat anti-rabbit IgG were pur- 
chased from Sigma. Rabbit anti-human vitronectin polyclonal 
antibodies were from Calbiochem. DEAE Sephacel and Blue 
Sepharose Cl-6B were purchased from Pharmacia. Hydroxyapatite 
and molecular weight markers for SDS-PAGE were from Bio-Rad. 
[Y-~‘P]ATP (3000 Ci/mmol) was obtained from Amersham. 
Nitrocellulose paper (0.45 Frn) was from Schleicher and Schuell. 
2.2. Procedures carried out by methods described in the literature 
Protein concentration was determined by the method of Bradford 
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[14]. SDS-PAGE was carried out according to the procedure describ- 
ed by Laemmli [15], either under reducing conditions (R, with 
2-mercaptoethanol), or under non-reducing conditions (NR, without 
2-mercaptoethanol). The gels were fixed and stained with a 
Coomassie blue solution (0.25%) in 50% methanol and 7% acetic 
acid. Destaining was carried out with a 20% isopropanol solution 
containing acetic acid (7’J/o). Gels assayed for radioactively labeled 
proteins were dried under vacuum and autoradiographed at -20°C 
using Agfa X-ray film. Alternatively, the lanes of such gels were cut 
out and their radioactivity was counted in a scintillation counter us- 
ing a toluene-based scintillant. Immunoblotting was carried out as 
described by Towbin et al. [16]. 
2.3. Vitronectin 
Vitronectin was prepared from freshly-frozen human plasma using 
a purification procedure described elsewhere [13]. Our preparations 
usually contained two molecular forms of this protein: V75 - a one 
chain (75 kDa) form, and Vss + 10 - a proteolytically clipped, two- 
chain protein (65 kDa and 10 kDa) held together by a disulfide bridge 
12,8,9,171. 
2.4. The catalytic subunit of PKA 
Pure catalytic subunit of PKA was prepared according to Beavo et 
al. [18] and assayed as described by Kupfer et al. [19]. The resulting 
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Fig. 1. Protein staining and immunoblotting of purified vitronectm 
and its enzymatic labeling with the catalytic subunit of PKA. Samples 
(10 pg) of vitronectin [13] were subjected to SDS-PAGE-R. (A) (7% 
gel) The gel was stained with Coomassie blue. (B) (7% gel) Im- 
munoblotting was carried out with rabbit anti-human vitronectin and 
goat anti-rabbit IgG conjugated with peroxidase. (C,D) (7-20% gels) 
A vitronectin preparation (final concentration 2.7 CM) was 
phosphorylated with the catalytic subunit of PKA (25 nM) and 
[y’*P]ATP (50 CM, 0.5 Ci/mmol) either at pH 7.5 in the absence 
(lane C) or in the presence (lane D) of a three-molar excess of 
heparin. In both lanes C and D, the reaction was allowed to proceed 
for 30 min at 30°C then arrested by addition of sample buffer and 
boiling (3 min at 95°C). After SDS-PAGE-R the gels were subjected 
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Fig. 2. Effect of heparin on the relative PKA phosphorylation of 
Vss + ia and V75 at different pH values. Vitronectin (final concentra- 
tion 1.5 PM) containing a V65+ 10 to V75 ratio of - 1.2 was pre- 
incubated in the absence or in the presence of heparin (a 3-fold molar 
excess, where indicated) for 2 h at 22°C in the following buffers: Mes 
50 mM, pH 6.0 or 6.5; Hepes 50 mM, pH 7.0 or 7.5, Tris 50 mM, 
pH 8.0 and 9.0. Phosphorylation of vitronectin was allowed to pro- 
ceed (15 min at 30°C) with the catalytic subunit of PKA (25 nM), 
[y-‘*P]ATP (10 pM, 0.5 Ci/mmol) and Mg(CH$OO)a (10 mM) (all 
final concentrations). The reaction was arrested by addition of sam- 
ple buffer and boiling (3 min at 95’C). The samples were then sub- 
jected to SDS-PAGE-R (10% gels). The Coomassie blue stained 
to autoradiography. bands were excised and their radioactivity was counted. 
enzyme preparations had a specific activity of 8-13 units/mg. One 
unit of enzyme activity is defined as the amount of enzyme which 
catalyzes the transfer of 1 amol of [“PI from [y-“P]ATP onto 
histone H2b per min at pH 6.5 and 30°C. 
2.5 Identification and assay of vitronectin by phosphorylation with 
the catalytic subunit of PKA (131 
Aliquots of the samples to be assayed (platelet-free plasma, frac- 
tionated or purified vitronectin) were added to a reaction mixture 
(final volume 50 ~1) which contained the following constituents at the 
indicated final concentrations: pure catalytic subunit of PKA (2.5 
pg/ml), Mg(CH&OO)z (10 mM), [y’*P]ATP (10 $M, 50 Ci/mmol) 
Hepes (50 mM, pH 7.5). Phosphorylation was allowed to proceed for 
10 min at 30°C and arrested by addition of 12 pl of the sample buffer 
to yield the following final composition: SDS (2vo), 
2-mercaptoethanol (0.75 M), glycerol (IO%), Tris HCl buffer (25 
mM, pH 6.7) bromophenol blue (0.1 mg/ml). The samples were sub- 
jected to SDS-PAGE under R or NR conditions and autoradiography 
or counting. Where specified, the vitronectin samples were incubated 
with heparin (at the indicated concentration) prior to their 
phosphorylation with PKA. 
3. RESULTS AND DISCUSSION 
At physiological pH, the catalytic subunit of PKA 
differentiates between the single-chain (VT,) form of 
vitronectin and its endogenously clipped two-chain 
(V65+ 10) form. It phosphorylates v75 but not V65+ 10 
(Fig. 1C). This distinction is intriguing since PKA was 
shown to phosphorylate Ser378 in V~S, and since the 
complete PKA recognition site (in this case Arg-Arg- 
Pro-Ser-Arg) is still present at the C terminal edge of 
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Fig. 3. Effect of heparin and other glycosaminoglycans (GAG) on the 
phosphorylation of the 75 and 65 kDa polypeptide bands of vitronec- 
tin. Duplicate samples (50 ~1) containing vitronectin (2 PM) in Hepes 
(50 mM), pH 7.5 were incubated (120 min at 23°C) with heparin, 
heparan sulfate, dextran sulfate and chondroitin sulfate C. The 
phosphorylation reaction was initiated by the addition of the catalytic 
subunit of PKA (4 ~1 of 1 mglml) and 6 pi of a solution containing 
Mg(CH3C00)2 (100 mM) and [T-~‘P]ATP (0.5 mM, 0.5 Wmmol). 
The reaction was arrested after different times (O-15 min) by mixing 
the samples with 14 ~1 of a solution containing SDS (10%) and 
2-mercaptoethanol(3.75 M) and boiling for 3 min. The incorporation 
of [32P) was determined quantitatively by counting the 75 kDa and 
65 kDa Coomassie blue stained bands of vitronectin excised from a 
dry 10% SDS-PAGE-R. 
the 65 kDa chain in V65 + IO (10,121. We assumed 
therefore that the endogenous cleavage which converts 
V~S into V65+ 10 may bring about a conformational 
change whereby Ser378 becomes ‘buried’ and inaccessi- 
ble to the kinase. Indeed, it is possible to achieve a 
phosphorylation of Ser378 in V65 + 10 if the reaction is 
carried out in the presence of heparin (Fig. 1, compare 
lanes C and D). Furthermore, if the relative 
stoichiometry of phosphorylation of V65 + 10 and V7s is 
determined as a function of pH, it can be seen that in 
the presence of heparin, not only V75 but also V65 + 1~ 
undergoes a quantitative phosphorylation at 
physiological pH (Fig. 2). In the absence of heparin 
such a VSS + IO / V7s phosphorylation ratio can be 
achieved only at pH 6.0, where the structure of V65 + ,O 
is presumably loosened to make Ser378 accessible to 
phosphorylation. At pH 7.5, the stoichiometry of 
phosphorylation of V6S + 10 was found to be 0.99 + 
0.02 mol 32P/mol in the presence of heparin but only 
0.15 f 0.03 mol in the absence of this GAG. 
It should be emphasized that the hep~in-stimulated 
phosphorylation of the two molecular forms of 
vitronectin results from a heparin effect on vitronectin 
itself and not on PKA. In control experiments imilar 
to those shown in Fig. lD, we found that heparin ac- 
tually reduces the rate of phosphorylation of a protein 
(histone IIb) and a peptide (Leu-Arg-Arg-Ala-Ser-Leu- 
Gly [20]) which are commonly used substrates of PKA 
[21]. In the presence of heparin the rate of 
phosphorylation of the protein is reduced - 1.6-fold 
and that of the peptide is reduced -3.6-fold. It seems 
therefore that heparin exerts its major effect on the 
conformation of VSS+ 10, exposing its otherwise 
‘buried’ Ser378 and allowing its rapid stoichiometric 
phosphorylation. The physiological proteolytic nicking 
of V~S to yield VSS + 10 thus yields a structurally flexible 
form of vitronectin which can now ‘sense’ and confor- 
mation~y respond to heparin. 
In an attempt to assess the possible physiological 
significance of the heparin dependency in the 
phosphorylation of v6S + IO and V~S, we compared the 
ability of several GAG analogs to stimulate this 
phosphorylation. As seen in Fig. 3, heparan sulfate (a 
widely distributed GAG found in the arteries, on cell 
surfaces and the basal laminae) also brings about a 
significant stimulation of the PKA phosphorylation of 
both V75 and V65 + IO, but chondroitin sulfate-C does 
not. Interestingly, the highly charged heparin analog 
dextran sulfate stimulates the phosphorylation of 
vitronectin even better than heparin (Fig. 3), suggesting 
that the negative charges of heparin play an important 
role in this stimulation, probably interfering with the 
ionic interactions between the cluster of basic amino 
acids found at the heparin-binding domain of vitronec- 
tin (A) and repelling the negatively charged domain (B) 
(Scheme I). 
Furthermore, when recalcified plasma is 
phosphorylated by PKA, then chromatographed on im- 
mobilized heparin, the phosphorylated V75 is excluded 
at physiological pH and ionic strength, whereas V65 + $0 
is adsorbed on the column and requires a higher ionic 
strength to be detached (Fig. 4), suggesting that under 
physiological conditions V65 .+ 10 has a distinctly higher 
affinity for heparin (see also [22]). The structural 
change resulting from the cleavage of V75 into V65 + 1~ 
may therefore promote the binding of vitronectin to 
tissue surfaces that contain GAGS such as heparan 
sulfate or heparin. In this context it is noteworthy that 
the binding of heparin to vitronectin was shown to be 
enhanced by thrombospondin [23] and by the throm- 
bin-antithrombin III complex [ 191. 
On the basis of previous findings and of the observa- 
tions reported here, we propose that the conforma- 
tiOna1 change triggered by the V75 to V65 + 10 conversion 
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Scheme I. Schematic representation of the conformation of VbS + 10 at physiological pH, in the absence and in the presence of heparin or heparan 
sulfate. Note the electrostatic interactions between the positively charged heparin binding domain (A) and the negative& charged N-term&G do- 
main (8). Also note that in the absence of heparin, Ser3?* (arrow) is inaccessible to phosphoryiation by PICA (buried), and that upon binding 
of heparin (or heparan sulfate), Set3’* becomes exposed. 
and the subsequent hep~in-de~ndent PKA heparin) dependent; (c) Heparan s&fate is present in 
phosphorylation could be a physiological regulatory the sub-endothelium of blood vessels and in platelets 
process. This proposal stems from the following facts: 12,251; (d) Plasma V65+ 10 adheres to immobilized 
(a) VGJ + 10 is a normal constituent of human blood, heparin at physiological pH and ionic strength (see also 
present in an equal amount to VYS in 38-59’70 of the [26]); (e) The Km’s of PKA for vitronectin, ATP and 
population [ 17,241, and in a large excess over VX in up MgZ f are compatible with the concentrations of these 
to 22% of the population [24]; (b) The PICA blood constituents at the locus of a hemostatic event 
phosphoryiation of Vas+ 10 is heparan sulfate (or (Korc-Grodzicki and Shaltiel, unpublished results); and 
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Fig. 4. Immobilized heparin separates plasma V75 from Vss + 1s under 
physiological pH and ionic strength. To human plasma (250 ~1) we 
added CaClz (final concentration 20 mM). After standing for 1 h at 
4”C, the fibrin clot was removed by centrifugation (5 min at 12000 
rpm) and the supernatant was subjected to phosphorylation with the 
C subunit of PKA and [y-“P]ATP at pH 6.0 (see section 2), then 
dialyzed against a sodium phosphate buffer (25 mM, pH 6.0) which 
included benzamidine (2 mM) and glutathione (1 mM), The sample 
was then applied on a heparin-agarose column (0.5 x4.0 cm) 
equilibrated with the same buffer. The column was washed with 10 
ml of the same buffer and then elution was attempted with 10 ml of 
a sodium phosphate buffer (50 mM, pH 7.2), then with 10 ml of the 
sodium phosphate buffer (50 mM, pH 7.2) which also contained 0.5 
M NaCl. Fractions (0.5 ml) were collected, counted, and each of the 
peak fractions (I, II and III) was subjected to SDS-PAGE (7% gels) 
under R and NR conditions, then to autoradiography (right panels) 
to detect the presence of V75 and of Vss + ,o. 
(f) PKA is specifically released from physiologically 
stimulated platelets alongside with its co-substrate ATP 
[11,12]. In any case, the heparin-dependent PKA 
phosphorylation of V65+ 10 should be kept in mind 
when working with heparinized blood, and in studying 
the effect of heparin as an anticoagulant. 
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